Vimian Group AB (publ)

DB:0V0 Stock Report

Market Cap: €2.0b

Vimian Group Valuation

Is 0V0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0V0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0V0 (€3.8) is trading below our estimate of fair value (€5.01)

Significantly Below Fair Value: 0V0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0V0?

Key metric: As 0V0 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0V0. This is calculated by dividing 0V0's market cap by their current revenue.
What is 0V0's PS Ratio?
PS Ratio5.6x
Sales€352.39m
Market Cap€1.99b

Price to Sales Ratio vs Peers

How does 0V0's PS Ratio compare to its peers?

The above table shows the PS ratio for 0V0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
PHH2 Paul Hartmann
0.3xn/a€745.9m
EUZ Eckert & Ziegler
3.2x6.3%€897.2m
AFX Carl Zeiss Meditec
2.5x8.0%€5.1b
DRW3 Drägerwerk KGaA
0.2x4.2%€792.0m
0V0 Vimian Group
5.6x14.1%€22.9b

Price-To-Sales vs Peers: 0V0 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does 0V0's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$830.14m
PHH2 Paul Hartmann
0.3xn/aUS$781.42m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
0V0 5.6xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0V0 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the European Medical Equipment industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is 0V0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0V0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.6x
Fair PS Ratio4.1x

Price-To-Sales vs Fair Ratio: 0V0 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0V0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.80
€4.17
+9.7%
15.6%€4.80€3.12n/a6
Nov ’25€3.74
€4.02
+7.4%
22.4%€4.80€2.46n/a6
Oct ’25€4.08
€3.90
-4.4%
22.9%€4.87€2.46n/a7
Sep ’25€3.60
€3.61
+0.4%
20.0%€4.49€2.42n/a7
Aug ’25€2.89
€3.45
+19.5%
17.3%€4.30€2.42n/a7
Jul ’25€2.98
€3.37
+13.2%
17.6%€4.26€2.42n/a7
Jun ’25€2.88
€3.40
+18.1%
18.8%€4.38€2.42n/a7
May ’25€2.50
€3.35
+34.1%
22.5%€4.38€2.31n/a6
Apr ’25€2.57
€3.36
+31.1%
22.5%€4.38€2.35n/a6
Mar ’25€2.59
€3.48
+34.3%
20.8%€4.46€2.49n/a7
Feb ’25€2.50
€3.30
+32.4%
18.8%€4.30€2.48n/a7
Jan ’25€2.62
€3.32
+26.7%
18.8%€4.30€2.48n/a7
Dec ’24€2.22
€3.35
+51.2%
20.3%€4.30€2.41n/a6
Nov ’24€2.11
€3.61
+71.4%
16.8%€4.23€2.41€3.746
Oct ’24€1.96
€3.72
+89.7%
9.9%€4.19€3.10€4.086
Sep ’24€2.61
€3.72
+42.6%
9.9%€4.19€3.10€3.606
Aug ’24€2.37
€3.77
+58.9%
9.1%€4.39€3.28€2.896
Jul ’24€2.36
€3.79
+60.4%
9.0%€4.39€3.28€2.986
Jun ’24€2.74
€3.86
+41.1%
9.5%€4.39€3.28€2.886
May ’24€3.29
€3.64
+10.7%
12.3%€4.40€2.96€2.506
Apr ’24€2.89
€3.65
+26.3%
12.4%€4.40€2.96€2.576
Mar ’24€2.16
€4.10
+89.6%
21.5%€5.45€3.07€2.596
Feb ’24€2.49
€4.25
+70.8%
20.2%€5.45€3.18€2.506
Jan ’24€2.44
€4.32
+77.0%
20.0%€5.45€3.18€2.626
Dec ’23€3.41
€4.32
+26.8%
20.0%€5.45€3.18€2.226
Nov ’23€3.24
€5.71
+76.4%
30.8%€7.80€2.73€2.115

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

7D

4.4%

1Y

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.9%

1Y

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

7D

1.5%

1Y

17.7%